GLMD News and Press, Galmed Pharmaceuticals Ltd. From 08/28/25

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire TEL AVIV, Israel , Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutic...

2025-08-27 13:44:42 ET More on Viking Therapeutics, Altimmune, etc. Viking: Still On Track, But The Compass Needs Recalibration Viking Therapeutics: Panic Creates Opportunity Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell ...

Trillion Energy International Inc (TRLEF) is expected to report $0 for Q2 2025 ModivCare Inc. (MODV) is expected to report $-0.61 for Q2 2025 Guess? Inc. (GES) is expected to report $0.14 for Q2 2026 Yuanbao Inc. (YB) is expected to report for quarter end 2025-06-30 NVIDIA Corpora...

Galmed Pharmaceuticals Ltd. (GLMD) is expected to report for quarter end 2025-06-30

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value PR Newswire An amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary share...

2025-05-27 18:47:42 ET Galmed Pharmaceuticals Ltd. (GLMD) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.31%. The average open to low on the day of earnings was -6.29%. The average op...

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH PR Newswire Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, un...

2025-05-22 08:06:26 ET More on Galmed Seeking Alpha’s Quant Rating on Galmed Financial information for Galmed Read the full article on Seeking Alpha For further details see: Galmed GAAP EPS of -$0.62 beats by $0.27

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical...

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models PR Newswire Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads to significant inhibi...